The diabetic myocardium

Current Diabetes Reports

Volumn 6, Issue 1, 2006, Pages 36-41

  Marwick, Thomas H ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FATTY ACID; GLUCOSE;

AUTONOMIC NEUROPATHY; CELL METABOLISM; CLINICAL FEATURE; CORONARY ARTERY DISEASE; DIABETES CONTROL; DIABETES MELLITUS; DIASTOLE; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; ENZYME INHIBITION; EVIDENCE BASED MEDICINE; FATTY ACID METABOLISM; FREQUENCY ANALYSIS; HEART DISEASE; HEART FAILURE; HUMAN; INTERSTITIUM; MEDICAL DOCUMENTATION; MUSCLE CELL; MYOCARDIAL DISEASE; REVIEW; SENSITIVITY ANALYSIS; SYSTOLE; VASCULAR DISEASE;

DIABETES MELLITUS; DIABETIC ANGIOPATHIES; HEART; HEART DISEASES; HUMANS; RISK FACTORS; VASCULAR DISEASES;

EID: 33645287029     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-006-0049-0     Document Type: Review

References (52)

1. Fisher M: Diabetes and atherogenesis. Heart 2004, 90:336-340.
2. Bell DS: Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 2003, 26:2433-2441.
3. Rubler S, Dlugash J, Yuceoglu YZ, et al.: New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972, 30:595-602.
4. Coughlin SS, Pearle DL, Baughman KL, et al.: Diabetes mellitus and risk of idiopathic dilated cardiomyopathy. The Washington, DC Dilated Cardiomyopathy Study. Ann Epidemiol 1994, 4:67-74.
5. Redfield MM, Jacobsen SJ, Burnett JC Jr. et al.: Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003, 289:194-202.
6. Kannel WB, McGee D: Diabetes and cardiovascular disease: the Framingham study. JAMA 1979, 241:2035-2038.
7. de Groote P, Lamblin N, Mouquet F, et al.: Impact of diabetes mellitus on long-term survival in patients with congestive heart failure. Eur Heart J 2004, 25:656-662.
8. Fang ZY, Sharman J, Prins JB, Marwick TH: Determinants of exercise capacity in patients with type 2 diabetes. Diabetes Care 2005, 28:1643-1648.
9. Hunt SA, Abraham WT, Chin M, et al.: ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult - Summary Article A Report of the American College of Cardiology /American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005, 46:1116-1143.
10. Davies M, Hobbs F, Davis R, et al.: Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study. Lancet 2001, 358:439-444.
11. McCullough PA, Nowak RM, McCord J, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 2002, 106:416-422.
12. Fang ZY, Schull-Meade R, Leano R, et al.: Screening for heart disease in diabetic subjects. Am Heart J 2005, 149:349-354.
13. Zabalgoitia M, Ismaeil MF, Anderson L, Maklady FA: Prevalence of diastolic dysfunction in normotensive, asymptomatic patients with well-controlled type 2 diabetes mellitus. Am J Cardiol 2001, 87:320-323.
14. Boyer JK, Thanigaraj S, Schechtman KB, Perez JE: Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. Am J Cardiol 2004, 93:870-875.
15. Trost SU, Belke DD, Bluhm WF, et al.: Overexpression of the sarcoplasmic reticulum Ca(2+)-ATPase improves myocardial contractility in diabetic cardiomyopathy. Diabetes 2002, 51:1166-1171.
16. Flarsheim CE, Grupp IL, Matlib MA: Mitochondrial dysfunction accompanies diastolic dysfunction in diabetic rat heart. Am J Physiol 1996, 271:H192-H202.
17. Yu CM, Lin H, Yang H, et al.: Progression of systolic abnormalities in patients with "isolated" diastolic heart failure and diastolic dysfunction. Circulation 2002, 105:1195-1201.
18. Astorri E, Fiorina P, Contini GA, et al.: Isolated and preclinical impairment of left ventricular filling in insulin-dependent and non-insulin-dependent diabetic patients. Clin Cardiol 1997, 20:536-540.
19. Friedman NE, Levitsky LL, Edidin DV, et al.: Echocardiographic evidence for impaired myocardial performance in children with type I diabetes mellitus. Am J Med 1982, 73:846-850.
20. Vered A, Battler A, Segal P, et al.: Exercise-induced left ventricular dysfunction in young men with asymptomatic diabetes mellitus (diabetic cardiomyopathy). Am J Cardiol 1984, 54:633-637.
21. Fang ZY, Yuda S, Anderson V, et al.: Echocardiographic detection of early diabetic myocardial disease. J Am Coll Cardiol 2003, 41:611-617.
22. Garvey WT, Hardin D, Juhaszova M, Dominguez JH: Effects of diabetes on myocardial glucose transport system in rats: implications for diabetic cardiomyopathy. Am J Physiol 1993, 264:H837-H844.
23. Rodrigues B, Cam MC, Kong J, et al.: Strain differences in susceptibility to streptozotocin-induced diabetes: effects on hypertriglyceridemia and cardiomyopathy. Cardiovasc Res 1997, 34:199-205.
24. Rodrigues B, Cam MC, McNeill JH: Metabolic disturbances in diabetic cardiomyopathy. Mol Cell Biochem 1998, 180:53-57.
25. Malone JI, Schocken DD, Morrison AD, Gilbert-Barness E: Diabetic cardiomyopathy and carnitine deficiency. J Diabetes Complications 1999, 13:86-90.
26. Kita Y, Shimizu M, Sugihara N, et al.: Correlation between histopathological changes and mechanical dysfunction in diabetic rat hearts. Diabetes Res Clin Pract 1991, 11:177-188.
27. Litwin SE, Raya TE, Anderson PG, et al.: Abnormal cardiac function in the streptozotocin-diabetic rat. Changes in active and passive properties of the left ventricle. J Clin Invest 1990, 86:481-488.
28. Stroedter D, Schmidt T, Bretzel RG, Federlin K: Glucose metabolism and left ventricular dysfunction are normalized by insulin and islet transplantation in mild diabetes in the rat. Acta Diabetol 1995, 32:235-243.
29. Thompson EW: Structural manifestations of diabetic cardiomyopathy in the rat and its reversal by insulin treatment. Am J Anat 1988, 182:270-282.
30. Sykes CA, Wright AD, Malins JM, Pentecost BL: Changes in systolic time intervals during treatment of diabetes mellitus. Br Heart J 1977, 39:255-259.
31. Shapiro LM, Leatherdale BA, Coyne ME, et al.: Prospective study of heart disease in untreated maturity onset diabetics. Br Heart J 1980, 44:342-348.
32. von Bibra H, Hansen A, Dounis V, et al.: Augmented metabolic control improves myocardial diastolic function and perfusion in patients with non-insulin dependent diabetes. Heart 2004, 90:1483-1484.
33. Picano E, Pelosi G, Marzilli M, et al.: In vivo quantitative ultrasonic evaluation of myocardial fibrosis in humans. Circulation 1990, 81:58-64.
34. Fiordaliso F, Li B, Latini R, et al.: Myocyte death in streptozotocin-induced diabetes in rats in angiotensin II-dependent. Lab Invest 2000, 80:513-527.
35. Kajstura J, Fiordaliso F, Andreoli AM, et al.: IGF-1 overexpression inhibits the development of diabetic cardiomyopathy and angiotensin II-mediated oxidative stress. Diabetes 2001, 50:1414-1424.
36. Fischer VW, Barner HB, Leskiw ML: Capillary basal laminar thickness in diabetic human myocardium. Diabetes 1979, 28:713-719.
37. Kawaguchi M, Techigawara M, Ishihata T, et al.: A comparison of ultrastructural changes on endomyocardial biopsy specimens obtained from patients with diabetes mellitus with and without hypertension. Heart Vessels 1997, 12:267-274.
38. Fang ZY, Najos-Valencia O, Leano R, Marwick TH: Patients with early diabetic heart disease demonstrate a normal myocardial response to dobutamine. J Am Coll Cardiol 2003, 42:446-453.
39. Strauer BE, Motz W, Vogt M, Schwartzkopff B: Impaired coronary flow reserve in NIDDM: a possible role for diabetic cardiopathy in humans. Diabetes 1997, 46(suppl 2):S119-S124.
40. Sakamoto K, Yamasaki Y, Nanto S, et al.: Mechanism of impaired left ventricular wall motion in the diabetic heart without coronary artery disease. Diabetes Care 1998, 21:2123-2128.
41. Hansen A, Johansson BL, Wahren J, von Bibra H: C-peptide exerts beneficial effects on myocardial blood flow and function in patients with type 1 diabetes. Diabetes 2002, 51:3077-3082.
42. Mantysaari M, Kuikka J, Mustonen J, et al.: Measurement of myocardial accumulation of 123I-metaiodobenzyl-guanidine for studying cardiac autonomic neuropathy in diabetes mellitus. Clin Auton Res 1996, 6:163-169.
43. Hartmann F, Ziegler S, Nekolla S, et al.: Regional patterns of myocardial sympathetic denervation in dilated cardiomyopathy: an analysis using carbon-11 hydroxyephedrine and positron emission tomography. Heart 1999, 81:262-270.
44. Allman KC, Stevens MJ, Wieland DM, et al.: Noninvasive assessment of cardiac diabetic neuropathy by carbon-11 hydroxyephedrine and positron emission tomography. J Am Coll Cardiol 1993, 22:1425-1432.
45. Erbas T, Erbas B, Kabakci G, et al.: Plasma big-endothelin levels, cardiac autonomic neuropathy, and cardiac functions in patients with insulin-dependent diabetes mellitus. Clin Cardiol 2000, 23:259-263.
46. Scognamiglio R, Fasoli C, Ferri M, et al.: Myocardial dysfunction and abnormal left ventricular exercise response in autonomic diabetic patients. Clin Cardiol 1995, 18:276-282.
47. Scognamiglio R, Avogaro A, Casara D, et al.: Myocardial dysfunction and adrenergic cardiac innervation in patients with insulin-dependent diabetes mellitus. J Am Coll Cardiol 1998, 31:404-412.
48. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group [no authors listed]. BMJ 1998, 317:703-713.
49. Tuomilehto J, Rastenyte D, Birkenhager WH, et al.: Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999, 340:677-684.
50. Fang ZY, Schull-Meade R, Downey M, et al.: Determinants of subclinical diabetic heart disease. Diabetologia 2005, 48:394-402.
51. Asif M, Egan J, Vasan S. et al.: An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness. Proc Natl Acad Sci U S A 2000, 97:2809-2813.
52. Liu J, Masurekar MR, Vatner DE, et al.: Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart. Am J Physiol Heart Circ Physiol 2003, 285:H2587-H2591.